Previous 10 | Next 10 |
home / stock / otlkw / otlkw news
CRANBURY, N.J., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in r...
Topline results from the NORSE 1 study of ONS-5010 expected to be announced in the third quarter of calendar 2020 Enrollment in the NORSE 2 study underway SPA agreement reached with FDA for NORSE 4, 5 and 6 studies CRANBURY, N.J., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Outlook Ther...
ONS-5010, an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two clinical trials to treat wet age-related macular degeneration (wet AMD – NORSE 1 and 2). SPAs for clinical trial protocols for NORSE 4 for branch retinal vein...
CRANBURY, N.J., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it is scheduled to participate in the Ladenburg Thalmann 2019 Healthcare Conference being held at the Sofitel New York in New York on September 24 ...
CRANBURY, N.J., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it is scheduled to participate in the H.C. Wainwright 21st Annual Healthcare Conference that is being held at the Lotte New York Palace Hotel in New...
CRANBURY, N.J., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, an ophthalmic bevacizumab product candidate for the treatment of wet age related macular...
CRANBURY, N.J., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”) today reported business highlights and financial results for its third quarter ended June 30, 2019. Recent Highlights: NORSE 2 (formerly “ONS-5010-002ȁ...
CRANBURY, N.J., July 16, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age rel...
CRANBURY, N.J., June 03, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age rela...
CRANBURY, N.J., May 15, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported business highlights and financial results for its second fiscal quarter ended March 31, 2019. Recent Highlights: FDA acceptance and activation of the I...
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Series A Warrant Company Name:
OTLKW Stock Symbol:
NASDAQ Market:
Outlook Therapeutics Inc. Series A Warrant Website:
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025...
Live video webcast on Tuesday, June 18 th at 12:00 PM ET ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; be...
LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD European Commission decision applies automatically to all 27 EU Member States and, within 30 days, also to Iceland, ...